Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. (Q38146713)

PubMed publication ID

24077405

29 August 2017

title

Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

1 reference

1 reference

Steven A Rosenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

Giao Q Phan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

language of work or name

1 reference

1 October 2013

1 reference

PubMed publication ID

29 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

page(s)

289-297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Allogeneic and autologous melanoma vaccines: where have we been and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Multiple vaccinations: friend or foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

The functional relationship of the interleukins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Lymphocyte activating factor promotes T-cell growth factor production by cloned murine lymphoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Guidelines for the safe administration of high-dose interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Successful treatment of melanoma brain metastases with adoptive cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Targeting tumours with genetically enhanced T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Treating cancer with genetically engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000406

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

21 January 2018

1 reference

12 December 2020

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

12 December 2020

Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity

1 reference

12 December 2020

LONGEVITY IN CANCER: A STUDY OF 293 CASES

1 reference

12 December 2020

Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy

1 reference

12 December 2020

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1 reference

12 December 2020

Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

10.1177/107327481302000406

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json

13 May 2020

PubMed publication ID

24077405

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6322197&resulttype=core&format=json